Adipotide Research Guide (Preclinical Overview)
Adipotide (also known as FTPP or pro-apoptotic peptide CKGGRAKDC-KLAKLAKKLAKLAK) represents a novel class of peptidomimetics engineered for targeted vascular disruption within white adipose tissue. Designed strictly for in vitro and preclinical laboratory investigation, this dual-domain synthetic peptide binds prohibitin receptors on fat-associated endothelial cells to induce mitochondrial apoptosis. This technical guide synthesizes current literature on its structural biology, receptor mechanics, preclinical animal model data, and laboratory handling requirements.
Quick answer
Adipotide (also known as FTPP or pro-apoptotic peptide CKGGRAKDC-KLAKLAKKLAKLAK) represents a novel class of peptidomimetics engineered for targeted vascular disruption within white adipose tissue. Designed strictly for in vitro and preclinical laboratory investigation, this dual-domain synthetic peptide binds prohibitin receptors on fat-associated endothelial cells to induce mitochondrial apoptosis. This technical guide synthesizes current literature on its structural biology, receptor mechanics, preclinical animal model data, and laboratory handling requirements.
Key takeaways
- In the domain of metabolic and vascular research, Adipotide (frequently designated as Fat Targeted Pro-apoptotic Peptide or FTPP) stands out as an experimental chimera designed to selectivity target the vascular supply of white adipose tissue (WAT).
- Adipotide is a engineered peptidomimetic comprising 21 amino acids with two distinct functional domains joined via a covalent peptide linkage.
- The molecular mechanism of Adipotide hinges upon its binding interaction with prohibitin-1 (PHB), a multifunctional membrane-associated protein overexpressed on the luminal surface of endothelial cells supplying white adipose tissue.
- Animal research involving Adipotide spans multiple species, providing valuable data regarding tissue selectivity, weight reduction velocity, and metabolic biomarker shifts.
Introduction to Adipotide (FTPP) and Targeted Peptide Design
In the domain of metabolic and vascular research, Adipotide (frequently designated as Fat Targeted Pro-apoptotic Peptide or FTPP) stands out as an experimental chimera designed to selectivity target the vascular supply of white adipose tissue (WAT). Developed originally as part of vascular homing research, the compound integrates a tissue-targeting motif with a pro-apoptotic sequence to initiate programmed cell death in specific capillary beds. Unlike conventional metabolic modulators that act on central nervous system receptors or enzymatic cascades to alter lipid storage, Adipotide targets the structural integrity of the microvasculature sustaining adipose deposits.
Preclinical investigation into Adipotide centers on its capacity to isolate receptor targets unique to the endothelium of hypertrophic fat tissue. By ablating the blood supply that feeds localized adipocytes, researchers use this compound to evaluate downstream vascular remodeling, oxygen deprivation dynamics, and subsequent lipid clearance in controlled laboratory models. For researchers evaluating novel targets in obesity and metabolic syndrome, understanding the dual-domain architecture of this compound is fundamental to designing robust in vitro and animal assays.
Chemical Structure and Dual-Domain Engineering
Adipotide is a engineered peptidomimetic comprising 21 amino acids with two distinct functional domains joined via a covalent peptide linkage. The targeted domain consists of a cyclic nonapeptide sequence—CKGGRAKDC—identified through in vivo phage display libraries for its high affinity toward specialized endothelial markers expressed preferentially in white fat tissue. The homing domain folds into a conformation capable of recognizing surface-exposed protein complexes on target cells while displaying minimal cross-reactivity with systemic vasculature.
The effector domain contains an amphipathic alpha-helical peptide motif, (KLAKLAK)2, which acts as a mitochondrial membrane disruptor. Outside the cell, this motif remains non-toxic; however, once internalized via receptor-mediated endocytosis, the cationic amphipathic structure inserts into the negatively charged mitochondrial inner membrane. This causes membrane depolarization, cytochrome c release, and execution of the caspase-dependent apoptotic cascade. The fusion of these two operational domains allows researchers to explore localized cell death while limiting broad systemic cytotoxicity in experimental models.
Mechanism of Action: Prohibitin Receptor Binding and Apoptosis
The molecular mechanism of Adipotide hinges upon its binding interaction with prohibitin-1 (PHB), a multifunctional membrane-associated protein overexpressed on the luminal surface of endothelial cells supplying white adipose tissue. Under standard physiological conditions, prohibitin functions primarily within the inner mitochondrial membrane to maintain organelle structure. However, in the hyper-vascularized microenvironment of expanding adipose tissue, prohibitin is localized to the plasma membrane, serving as an accessible vascular zip code.
In vitro binding assays indicate that the CKGGRAKDC targeting domain binds prohibitin with high specificity. Upon receptor occupancy, the cell internalizes the receptor-peptide complex through receptor-mediated endocytosis. Once inside the cytoplasm, the pro-apoptotic (KLAKLAK)2 domain targets the organelle membrane, disrupting transmembrane potential and triggering the release of pro-apoptotic factors such as Cytochrome C and Smac/DIABLO. This event activates Caspase-9 and Caspase-3, driving rapid apoptosis of the vascular endothelial cell. Starved of blood supply and oxygen, adjacent adipocytes undergo secondary necrosis and undergo phagocytic clearance by macrophages.
Preclinical Observations in Rodent and Non-Human Primate Models
Animal research involving Adipotide spans multiple species, providing valuable data regarding tissue selectivity, weight reduction velocity, and metabolic biomarker shifts. In rodent assays involving diet-induced obese (DIO) mice, daily administration of Adipotide resulted in localized vascular regression in subcutaneous and visceral fat depots, accompanied by rapid reductions in total body mass and marked improvements in insulin sensitivity parameters.
Subsequent studies advanced to non-human primates (spontaneously obese rhesus macaques) to evaluate translation across higher mammalian models. In these controlled laboratory settings, subjects treated with Adipotide demonstrated significant reductions in body weight, total fat mass, and abdominal circumference over a 28-day observation window. Imaging studies verified substantial reductions in visceral fat volume alongside improved serum glycemic markers. Researchers noted that weight loss was driven predominantly by loss of fat mass rather than lean tissue mass, validating the tissue-selective hypothesis of the compound's design.
Comparative Analysis: Pro-Apoptotic vs. Metabolic Research Peptides
When evaluating options within our research library hub, laboratory researchers frequently analyze how Adipotide compares to other metabolic and fat-modulating compounds. While conventional peptides act on hormonal pathways or mitochondrial efficiency, Adipotide operates through direct physical destruction of target vasculature. The table below highlights key functional distinctions among primary research compounds in this domain.
For instance, direct enzymatic inhibitors like 5-Amino-1MQ target intracellular nicotinamide N-methyltransferase (NNMT) to elevate NAD+ levels and accelerate cellular metabolism without causing vascular cytotoxicity. Similarly, synthetic growth hormone fragments like AOD-9604 act as lipolytic agonists that trigger lipolysis via beta-3 adrenergic pathways without inducing endothelial cell death. Mitochondrial-derived peptides like MOTS-c promote systemic insulin sensitivity through metabolic signaling and AMPK activation. Evaluating these distinct mechanistic pathways allows principal investigators to select the appropriate research peptides based on whether their experimental endpoints necessitate vascular ablation, metabolic signaling, or enzymatic inhibition.
Renal Considerations and Toxicological Profile in Laboratory Settings
A critical focus of the published Adipotide research guide literature involves characterizing the toxicological boundaries and dose-dependent side effects observed during preclinical evaluation. In both rodent and non-human primate studies, dose escalation was closely linked to transient alterations in renal function parameters. Because low levels of prohibitin are expressed within renal proximal tubule epithelia, high systemic concentrations of Adipotide can result in off-target binding within kidney tissue.
Histological and biochemical evaluations in primate models revealed localized tubular necrosis and transient elevations in blood urea nitrogen (BUN) and serum creatinine at higher dosage thresholds. Importantly, these renal biomarker elevations proved reversible upon cessation of compound administration. Nevertheless, these findings highlight the necessity for precise concentration calibration, careful urine specific gravity monitoring, and strict toxicological controls during in vivo laboratory experiments.
Purity Verification, Analytical Benchmarks, and Quality Assurance
Due to the structural complexity of a 21-amino-acid peptide containing a cyclic disulfide bridge, rigorous quality control is critical when sourcing Adipotide for scientific inquiry. Incomplete solid-phase peptide synthesis (SPPS) or improper oxidation during the cyclization step can yield misfolded variants or truncated sequences that lack targeting specificity or biological activity.
PX1 Research ensures that every production batch undergoes extensive analytical verification. Compounds are subjected to high-performance liquid chromatography (HPLC) to confirm sequence purity exceeding 98.0%, combined with mass spectrometry (MS) to verify precise molecular weight. Crucially, given that endothelial cell assays are highly sensitive to bacterial contaminants, all lots undergo stringent bacterial endotoxin testing via chromogenic LAL assays to maintain endotoxin levels strictly below <0.01 EU/mg. Every order includes a lot-specific Certificate of Analysis (COA) issued by an independent ISO 17025 accredited laboratory.
Reconstitution and Laboratory Storage Guidelines
To preserve the structural integrity of the cyclic motif and mitochondrial targeting sequence, research-grade Adipotide must be stored and handled under strict laboratory protocols. Lyophilized peptide powder should be maintained at -20°C for short-term projects or -80°C for long-term storage, protected from light and moisture ingress.
For reconstitution, investigators should utilize sterile bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4). The lyophilized cake should be allowed to equilibrate to room temperature before adding the diluent along the inner vial wall. Avoid violent agitation or vortexing; gentle swirl rotational movement is recommended to fully dissolve the cake without inducing shear stress or peptide aggregation. Reconstituted solutions should be aliquoted into single-use microcentrifuge tubes to prevent freeze-thaw degradation and stored at -80°C for experimental use. Institutional labs seeking bulk volume orders can access institutional accounts via our wholesale program.
Frequently Asked Questions
What is the primary target of Adipotide in research models?
Adipotide specifically targets prohibitin-1 (PHB) receptors expressed on the luminal surface of endothelial cells in the blood vessels supplying white adipose tissue.
How does Adipotide differ from standard lipolytic peptides?
Standard lipolytic peptides (such as AOD-9604) stimulate cellular lipolysis and fat breakdown via metabolic receptor signaling. Adipotide is a targeted pro-apoptotic agent that induces programmed cell death in white fat microvasculature, leading to localized ischemic tissue loss.
What purity levels are required for Adipotide research applications?
High-validity preclinical research requires peptide purity of at least 98.0% verified via HPLC and MS analysis, alongside low endotoxin levels (<0.01 EU/mg) to prevent confounding inflammatory responses in cell or animal models.
What renal markers should be monitored during preclinical Adipotide studies?
Preclinical protocols typically monitor serum creatinine, blood urea nitrogen (BUN), urine protein levels, and renal tubular histology due to potential low-level prohibitin expression in renal tubule cells.
How should lyophilized Adipotide be stored in the laboratory?
Lyophilized Adipotide should be stored at -20°C or -80°C in a desiccated environment protected from light. Reconstituted aliquots must be frozen at -80°C and protected from multiple freeze-thaw cycles.
What analytical documents accompany PX1 Research peptides?
Every lot supplied by PX1 Research includes a comprehensive, third-party ISO 17025 laboratory Certificate of Analysis (COA) detailing HPLC purity profiles, mass spec verification, and endotoxin assay results.
Is Adipotide suitable for human therapeutic or cosmetic use?
No. Adipotide is strictly an experimental research chemical supplied exclusively for in vitro and preclinical laboratory research use. It is not approved for human administration, clinical therapy, or diagnostic use.
What is the chemical composition of the targeting domain of Adipotide?
The targeting domain is a cyclic nonapeptide sequence (CKGGRAKDC) isolated through phage display screening that exhibits specific binding affinity for fat-associated vascular endothelial membranes.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.